Tenaya Therapeutics announced that it priced an underwritten, upsized initial public offering of common stock worth $180 million.
South San Francisco-based Tenaya develops therapies for rare generic disorders and more prevalent heart conditions through gene therapy, cellular regeneration and precision medicine. The company is actively exploring different routs of administration and different infusion- and injection-based methods for delivering its therapies.
Get the full story at our sister site, Drug Delivery Business News.